| Title |
Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, November 2017
|
| DOI | 10.1007/s00259-017-3877-z |
| Pubmed ID | |
| Authors |
Kambiz Rahbar, Martin Bögeman, Anna Yordanova, Maria Eveslage, Michael Schäfers, Markus Essler, Hojjat Ahmadzadehfar |
| Abstract |
Radioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage therapy in heavily pretreated patients with metastatic castration resistant prostate cancer. The aim of this retrospective study was to analyze response in patients receiving 3 cycles of Lu-PSMA. Seventy-one patients (median age: 72 years; range 44-87) received 3 cycles of RLT with Lu-PSMA (mean administered activity: 6.016 ± 0.543 GBq) every 8 weeks. Response was evaluated using serum PSA levels and a PSA decline ≥50% was considered as biochemical response. Additionally, any PSA decline after the first cycle was evaluated for further therapy effects after the second and third cycle. A total of 213 cycles were performed in 71 patients. Data for response and adverse events were available for all patients. A PSA decline ≥50% and some PSA decline occurred in 56% and 66% of the patients. Of 30 patients with a PSA response after the first cycle, 28 remained responders and 12/41 of non-responders responded to further therapy cycles. RLT with Lu-177-PSMA-617 shows respectable response rates. In this retrospective analysis, a relevant number of patients showed a delayed response, even if they did not respond to the first cycle of the therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Germany | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 60 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 18% |
| Researcher | 9 | 15% |
| Student > Doctoral Student | 6 | 10% |
| Student > Master | 5 | 8% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 9 | 15% |
| Unknown | 16 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 10% |
| Physics and Astronomy | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 17 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#3,314,569
of 25,608,265 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#301
of 3,535 outputs
Outputs of similar age
#59,053
of 337,707 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#4
of 42 outputs
Altmetric has tracked 25,608,265 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,535 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,707 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.